Systemic chemotherapy of advanced head and neck malignancies

Keith E. Dowell, Donna M. Armstrong, J. B. Aust, A. B. Cruz

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Several Phase II chemotherapy protocols were evaluated in patients with advanced malignancies; 158 were evaluable head and neck cases. The protocols were as follows: five‐drug combination (COMFP), four‐drug (COMF), (CCNU, Adriamycin, DTIC, and cytosine arabinoside. Insufficient numbers and data were received to adequately evaluate Yoshi 864, 5 Azacytidine, porfiromycin, BCNU, and Azaserine. Significant responses to therapy were noted in the four and five‐drug combinations in which 30–44% of the patients had 50% or greater regression, with an average duration of 2.2 months. Adriamycin and CCNU demonstrated lesser antitumor effects, while DTIC and cytosine arabinoside did not demonstrate significant antitumor activity in the head and neck areas. Usual toxicity consisted largely of nausea and vomiting, leukopenia, and thrombocytopenia. Alopecia was not pronounced in Adriamycin‐treated patients. It appears that combination chemotherapy had a higher response rate compared to single agents used in the different cooperative protocols.

Original languageEnglish (US)
Pages (from-to)1116-1120
Number of pages5
Issue number4
StatePublished - Apr 1975
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Systemic chemotherapy of advanced head and neck malignancies'. Together they form a unique fingerprint.

Cite this